217 related articles for article (PubMed ID: 26931114)
1. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine.
Poon LM; Kwong YL
Ann Hematol; 2016 Apr; 95(5):847-9. PubMed ID: 26931114
[No Abstract] [Full Text] [Related]
2. Complete healing of basal cell carcinoma under bendamustine and brentuximab vedotin therapy in a patient with cutaneous lymphoma.
Baykal C; Kutlay A; Buyukbabani N
Dermatol Ther; 2019 Jul; 32(4):e12934. PubMed ID: 30977947
[No Abstract] [Full Text] [Related]
3. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin.
Desai A; Telang GH; Olszewski AJ
Ann Hematol; 2013 Apr; 92(4):567-8. PubMed ID: 23086510
[No Abstract] [Full Text] [Related]
4. Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Pellegrini C; Maglie R; Argnani L; Pileri S; Zinzani PL
Hematol Oncol; 2016 Mar; 34(1):49-51. PubMed ID: 25243375
[No Abstract] [Full Text] [Related]
5. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
6. Nasal-type extranodal natural killer/T-cell lymphoma presenting with extensive leg ulcers.
Chia HY; Tey HL; Tan KB; Chong WS
Clin Exp Dermatol; 2009 Dec; 34(8):e693-5. PubMed ID: 20055838
[TBL] [Abstract][Full Text] [Related]
7. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
8. Cutaneous intravascular natural killer-cell lymphoma: a rare case and review of the literature.
Liao JB; Hsieh PP; Hwang YC; Lin SL; Wu CS
Acta Derm Venereol; 2011 Jun; 91(4):472-3. PubMed ID: 21394417
[No Abstract] [Full Text] [Related]
9. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
10. Successful treatment by using a modified SMILE regimen and autologous hematopoietic stem cell transplantation in a pediatric primary EBV-positive nodular NK/T cell lymphoma patient.
Li J; Ye J; Wang Y; Wang J; Fang Y
Ann Hematol; 2022 Feb; 101(2):433-435. PubMed ID: 33580279
[No Abstract] [Full Text] [Related]
11. Loss of Epstein-Barr virus-encoded RNA expression in cutaneous dissemination of natural killer/T-cell lymphoma.
Teo WL; Tan SY
J Clin Oncol; 2011 Apr; 29(12):e342-3. PubMed ID: 21282547
[No Abstract] [Full Text] [Related]
12. Extranodal NK/T-cell lymphoma, nasal type, possibly arising from chronic Epstein-Barr virus infection.
Seishima M; Yuge M; Kosugi H; Nagasaka T
Acta Derm Venereol; 2010; 90(1):102-3. PubMed ID: 20107744
[No Abstract] [Full Text] [Related]
13. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Intravascular NK/T-cell lymphoma mimic panniculitis clinically, case report and literature brief review.
Alhumidi A
Diagn Pathol; 2015 Jul; 10():107. PubMed ID: 26178620
[TBL] [Abstract][Full Text] [Related]
15. Series of extranodal natural killer/T-cell lymphoma, nasal type, with periorbital involvement.
Termote K; Dierickx D; Verhoef G; Jorissen M; Tousseyn T; Mombaerts I
Orbit; 2014 Aug; 33(4):245-51. PubMed ID: 24831171
[TBL] [Abstract][Full Text] [Related]
16. Case of extranodal natural killer/T-cell lymphoma, nasal type, accompanied by Epstein-Barr virus-positive nasopharyngeal carcinoma.
Senda N; Miyagaki T; Oka T; Itoigawa A; Kikuchi K; Kobayashi T; Nakamura F; Kurokawa M; Sugaya M; Sato S
J Dermatol; 2019 May; 46(5):e161-e163. PubMed ID: 30379350
[No Abstract] [Full Text] [Related]
17. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
Meister MT; Voss S; Schwabe D
Pediatr Blood Cancer; 2015 Nov; 62(11):2018-20. PubMed ID: 26109475
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma.
Kim SY; Cho SG; Kim SW; Choi BO; Park KS; Lim J; Min CK; Kim YG; Lee JW; Min WS
Ann Hematol; 2011 Jun; 90(6):693-9. PubMed ID: 21088967
[TBL] [Abstract][Full Text] [Related]
19. [Long-term administration of brentuximab vedotin in a patient with primary cutaneous anaplastic large cell lymphoma with peripheral blood involvement with leukemic change].
Kumekawa H; Mizuchi D; Iiyama M
Rinsho Ketsueki; 2018; 59(2):187-190. PubMed ID: 29515072
[TBL] [Abstract][Full Text] [Related]
20. Hydroa Vacciniforme-like Skin Lesions in Epstein-Barr-Virus-associated T-cell Lymphoproliferation with Subsequent Development of Aggressive NK/T-cell Lymphoma.
Toksoy A; Strifler S; Benoit S; Grigoleit GU; Knop S; Mielke S; Buder-Bakhaya K; Roth S; Goebeler M; Rosenwald A; Geissinger E; Wobser M
Acta Derm Venereol; 2017 Mar; 97(3):379-380. PubMed ID: 27826612
[No Abstract] [Full Text] [Related]
[Next] [New Search]
